Novavax Yönetim

Yönetim kriter kontrolleri 1/4

Novavax CEO'su John Jacobs, Jan2023 tarihinde atandı, in görev süresi 1.83 yıldır. in toplam yıllık tazminatı $ 7.30M olup, şirket hissesi ve opsiyonları dahil olmak üzere 9.1% maaş ve 90.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.03% ine doğrudan sahiptir ve bu hisseler MX$ 8.37M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.8 yıl ve 4.3 yıldır.

Anahtar bilgiler

John Jacobs

İcra Kurulu Başkanı

US$7.3m

Toplam tazminat

CEO maaş yüzdesi	9.1%
CEO görev süresi	1.8yrs
CEO sahipliği	0.03%
Yönetim ortalama görev süresi	1.8yrs
Yönetim Kurulu ortalama görev süresi	4.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

John Jacobs'un ücretlendirmesi Novavax'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$285m
Jun 30 2024	n/a	n/a	-US$294m
Mar 31 2024	n/a	n/a	-US$399m
Dec 31 2023	US$7m	US$663k	-US$545m

Tazminat ve Piyasa: John 'nin toplam tazminatı ($USD 7.30M ), MX pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 692.61K ).

Tazminat ve Kazançlar: John şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

John Jacobs (57 yo)

1.8yrs

Görev süresi

US$7,301,009

Tazminat

Mr. John Charles Jacobs, M.B.A., serves as Chief Executive Officer and Director of Novavax, Inc. since January 23, 2023 and serves as its President from January 23, 2023. He was Director of Life Sciences P...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
John Jacobs	President	1.8yrs	US$7.30m	0.030% MX$ 8.4m
John Trizzino	President & COO	less than a year	US$1.88m	0.018% MX$ 5.0m
James Kelly	Executive VP	3.3yrs	US$1.50m	0.0090% MX$ 2.5m
Mark Casey	Executive VP	less than a year	US$1.53m	Veri yok
Richard Crowley	Executive VP & COO	1.8yrs	Veri yok	Veri yok
Troy Morgan	Senior VP	no data	Veri yok	Veri yok
Erika Trahan	Associate Director of Investor & Public Relations	6.6yrs	Veri yok	Veri yok
Ian Watkins	Executive VP & Chief Human Resources Officer	1.3yrs	Veri yok	Veri yok
Silvia Taylor	Executive VP and Chief Corporate Affairs & Advocacy Officer	2.8yrs	Veri yok	Veri yok
Robert Walker	Senior VP & Chief Medical Officer	no data	Veri yok	Veri yok
Elaine O'Hara	Executive VP & Chief Strategy Officer	1.8yrs	Veri yok	0.0089% MX$ 2.5m
Ruxandra Draghia-Akli	EVP and Head of Research & Development	no data	Veri yok	Veri yok

1.8yrs

Ortalama Görev Süresi

59.5yo

Ortalama Yaş

Deneyimli Yönetim: NVAX * 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
John Jacobs	President	1.8yrs	US$7.30m	0.030% MX$ 8.4m
David Mott	Independent Director	4.4yrs	US$187.53k	0.032% MX$ 8.9m
Richard Douglas	Independent Director	14.8yrs	US$189.53k	0.027% MX$ 7.7m
Margaret McGlynn	Independent Director	3.9yrs	US$185.02k	0.0065% MX$ 1.8m
Gregg Alton	Independent Director	4.1yrs	US$175.28k	0.0065% MX$ 1.8m
Rachel King	Independent Director	6yrs	US$174.55k	0.012% MX$ 3.3m
Richard Rodgers	Independent Director	2.1yrs	US$191.78k	0.0065% MX$ 1.8m
James Young	Independent Chairman of the Board	14.6yrs	US$222.53k	0.039% MX$ 10.9m

4.3yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: NVAX * 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.3 yıldır).

Novavax Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Independent Chairman of the Board recently sold Mex$1.9m worth of stock

Novavax, Inc. Notifies Retirement of Filip Dubovsky as President, Research and Development, Effective as of June 30, 2024

President of Research & Development recently sold Mex$6.5m worth of stock

Novavax, Inc., Annual General Meeting, Jun 13, 2024

Novavax, Inc. Announces Changes to Executive Leadership Team

High number of new directors

Recent updates

Forecast breakeven date moved forward to 2025

Third quarter 2024 earnings released: US$0.76 loss per share (vs US$1.26 loss in 3Q 2023)

Novavax, Inc. Revises Revenue Guidance for the Full Year 2024

U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial

Novavax, Inc Announces Update on Covid-19-Influenza Combination and Stand-Alone Influenza Phase 3 Trial

Forecast breakeven date pushed back to 2026

Novavax, Inc. Updated 2024-2025 Nuvaxovid™ Covid-19 Vaccine Receives Authorization in the EU

Novavax Announces Availability of Updated Covid-19 Vaccine with Emergency Use Authorization from FDA

Novavax Announces That Novavax COVID-19 Vaccine, Adjuvanted Receives Emergency Use Authorization from the U.S. Food and Drug Administration

New minor risk - Profitability

Second quarter 2024 earnings released: EPS: US$1.09 (vs US$0.65 in 2Q 2023)

Forecast breakeven date pushed back to 2025

Novavax, Inc. Revises Revenue Guidance for the Full Year 2024

Novavax, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Independent Chairman of the Board recently sold Mex$1.9m worth of stock

Novavax, Inc. Submits Application to U.S. FDA for Updated Protein-Based 2024-2025 Formula COVID-19 Vaccine

Novavax, Inc. Notifies Retirement of Filip Dubovsky as President, Research and Development, Effective as of June 30, 2024

President of Research & Development recently sold Mex$6.5m worth of stock

New major risk - Financial position

Novavax, Inc. Revises Revenue Guidance for the Full Year 2024

First quarter 2024 earnings released: US$1.06 loss per share (vs US$3.41 loss in 1Q 2023)

Novavax, Inc. to Report Q1, 2024 Results on May 10, 2024

Novavax, Inc., Annual General Meeting, Jun 13, 2024

No longer forecast to breakeven

Full year 2023 earnings released: US$5.41 loss per share (vs US$8.42 loss in FY 2022)

Novavax, Inc. Provides Earnings Guidance for First Quarter and Full Year 2024

New minor risk - Profitability

Novavax, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Novavax, Inc. Announces The Taiwan Food and Drug Administration Grants Emergency Use Authorization for Nuvaxovid™ XBB.1.5 Dispersion for Injection Covid-19 Vaccine (Recombinant, Adjuvanted) (NVX-CoV2601) for Active Immunization to Prevent Covid-19 in Individuals Aged 12 and Older

Novavax, Inc. Announces Changes to Executive Leadership Team

New major risk - Shareholder dilution

Third quarter 2023 earnings released: US$1.26 loss per share (vs US$2.15 loss in 3Q 2022)

Novavax, Inc. Provides Earnings Guidance for the First Quarter of 2024

No longer forecast to breakeven

Novavax, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Novavax's Updates Nuvaxovid COVID-19 Vaccine Receives Positive CHMP Opinion in the EU

Forecast to breakeven in 2024

Novavax Receives Full Marketing Authorization for Prototype COVID-19 Vaccine Nuvaxovid™ in United Kingdom

Novavax, Inc. Announces Updated Protein-Based XBB Covid Vaccine Induced Neutralizing Responses Against Emerging Subvariants

Novavax, Inc. announced that it expects to receive $84.5 million in funding from SK bioscience Co.,Ltd.

New major risk - Financial position

Second quarter 2023 earnings released: EPS: US$0.65 (vs US$6.53 loss in 2Q 2022)

Novavax, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New minor risk - Profitability

New minor risk - Profitability

Novavax's Nuvaxovid™? Receives Full Marketing Authorization in the Eu for the Prevention of Covid

Novavax, Inc.(NasdaqGS:NVAX) dropped from Russell Midcap Index

Novavax's Nuvaxovid™ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU

No longer forecast to breakeven

Novavax, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings released: US$3.41 loss per share (vs US$2.66 profit in 1Q 2022)

No longer forecast to breakeven

Full year 2022 earnings released: US$8.42 loss per share (vs US$23.44 loss in FY 2021)

High number of new directors

Novavax, Inc. announced that it has received $6.75 million in funding from River Private Wealth

Novavax, Inc. Announces Chief Executive Officer Changes

Novavax, Inc. Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates

Novavax, Inc. has completed a Follow-on Equity Offering in the amount of $65 million.

Novavax, Inc. has completed a Follow-on Equity Offering in the amount of $65 million.

Novavax, Inc. Reaffirms Revenue Guidance for the Full Year 2022

Novavax, Inc. Appoints Richard J. Rodgers as Member of Its Audit Committee and as A Member of Its Compensation Committee

Novavax, Inc. Announces Nuvaxovid COVID-19 Vaccine Approval in Canada for Use as a Primary Series in Adolescents

No longer forecast to breakeven

Novavax, Inc. Announces the World Health Organization Issue an Updated Emergency Use Listing (EUL) for Nuvaxovid(TM) (NVX-CoV2373) COVID-19

Novavax Nuvaxovid COVID-19 Vaccine Receives Expanded Authorization in Canada as a Booster in Adults

Novavax, Inc. Announces Medicines and Healthcare Products Regulatory Agency Expands Conditional Marketing Authorization for Nuvaxovid™ COVID-19 Vaccine

Third quarter 2022 earnings released: US$2.15 loss per share (vs US$4.31 loss in 3Q 2021)

Novavax, Inc. Revises Revenue Guidance for the Year 2022

Novavax, Inc. to Report Q3, 2022 Results on Nov 08, 2022